S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Sinopharm Group Stock Price, News & Analysis (OTCMKTS:SHTDF)

$2.47
-0.12 (-4.44%)
(As of 12:27 PM ET)
Compare
Today's Range
$2.47
▼
$2.47
50-Day Range
$2.38
▼
$2.96
52-Week Range
$2.27
▼
$3.63
Volume
406 shs
Average Volume
6,328 shs
Market Capitalization
N/A
P/E Ratio
2.48
Dividend Yield
10.52%
Price Target
N/A
Stock AnalysisChartFinancialsHeadlinesShort Interest

Sinopharm Group MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.16mentions of Sinopharm Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.86 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SHTDF stock logo

About Sinopharm Group Stock (OTCMKTS:SHTDF)

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

SHTDF Stock Price History

SHTDF Stock News Headlines

November 24, 2023 | americanbankingnews.com
Sinopharm Group (OTCMKTS:SHTDF) Shares Pass Below 200 Day Moving Average of $2.94
November 8, 2023 | morningstar.com
Sinopharm Group Co Ltd SHTDF
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
May 12, 2023 | msn.com
Sinopharm Group (HKEX:1099) Price Target Increased by 8.31% to 29.48
April 13, 2023 | finance.yahoo.com
Pfizer signs strategic cooperation pact with China's Sinopharm
April 6, 2023 | msn.com
WHO chief expects COVID emergency to end this year
March 24, 2023 | msn.com
China approves its first mRNA Covid-19 vaccine
March 22, 2023 | news.yahoo.com
China approves first home-grown mRNA Covid vaccine
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
February 23, 2023 | forbes.com
Sinopharm Group
January 20, 2023 | news.yahoo.com
Sinopharm unit gets OK for clinical trials of mRNA COVID vaccine
January 20, 2023 | msn.com
Pharma major Sinopharm gets approval for clinical trials of mRNA Covid-19 vaccine
December 8, 2022 | reuters.com
Sinopharm's second Chinese herb shot is potent
December 2, 2022 | seekingalpha.com
Vaxxinity says COVID vaccine outperformed Astra and Sinopharm shots as booster
September 28, 2022 | seekingalpha.com
Merck in pact with Sinopharm to launch oral COVID-19 therapy in China
September 15, 2022 | msn.com
Sinopharm to boost local COVID vaccine production in Africa
September 7, 2022 | msn.com
China’s Sinovac to test Omicron-targeting vaccines in Chile
July 27, 2022 | msn.com
Daesang to set up joint venture with China Sinopharm International
July 17, 2022 | seekingalpha.com
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
July 4, 2022 | msn.com
Hong Kong could have 3 Omicron-targeting jabs by end of year, as health expert reveals Sinopharm hopes to make new vaccine available by December
June 27, 2022 | msn.com
China Donates 10 Mil Doses of Sinopharm COVID-19 Vaccines, Syringes
June 22, 2022 | usnews.com
Some Omicron Sub-Variants Escaping Antibodies From Sinopharm Shot -Chinese Study
June 21, 2022 | reuters.com
Some Omicron sub-variants escaping antibodies from Sinopharm shot - Chinese study
May 31, 2022 | msn.com
University of Hong Kong, Sinopharm launch city’s first trial for Omicron-targeting vaccine which could be ready in November
May 28, 2022 | seekingalpha.com
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
April 18, 2022 | seekingalpha.com
Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong
April 16, 2022 | msn.com
Sinopharm, Sinovac vaccine candidates for Omicron variant gets clearance for clinical trial
See More Headlines
Receive SHTDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medical Distribution
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SHTDF
CUSIP
N/A
CIK
1556605
Web
ir.sinopharmgroup.com.cn
Phone
86-21-2305-2666
Fax
N/A
Employees
114,766
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
2.48
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Qingming Yu (Age 59)
    Executive Chairman of the Board
    Comp: $888.91k
  • Mr. Yong Liu (Age 54)
    President & Executive Director
    Comp: $859.6k
  • Ms. Xiaojuan Li (Age 47)
    Chief Financial Officer
  • Mr. Yijian Wu (Age 53)
    Secretary to the Board, Company Secretary & Authorised Representative

Key Competitors

View All Competitors














SHTDF Stock Analysis - Frequently Asked Questions

How have SHTDF shares performed in 2023?

Sinopharm Group's stock was trading at $2.53 at the beginning of the year. Since then, SHTDF shares have decreased by 2.3% and is now trading at $2.4725.
View the best growth stocks for 2023 here.

Are investors shorting Sinopharm Group?

Sinopharm Group saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,438,900 shares, an increase of 62.0% from the October 31st total of 1,505,300 shares. Based on an average trading volume of 4,400 shares, the short-interest ratio is presently 554.3 days.
View Sinopharm Group's Short Interest.

Is Sinopharm Group a good dividend stock?

Sinopharm Group (OTCMKTS:SHTDF) pays an annual dividend of $0.26 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Sinopharm Group?

Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SHTDF) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -